Results 71 to 80 of about 3,621 (185)

Is the Efficacy of Milnacipran in Fibromyalgia Predictable? A Data-Mining Analysis of Baseline and Outcome Variables

The Clinical Journal of Pain, 2016
Objectives:Minalcipran has been approved for the treatment of fibromyalgia in several countries including Australia. Australian agency considered that the overall efficacy is moderate, although clinically significant, and could be translated into a real ...
Lilia Abtroun, P. Bunouf, R. Gendreau, O. Vitton   +3 more
semanticscholar   +1 more source

Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study

Journal of Pain Research, 2013
Lucinda Bateman,1 Robert H Palmer,2 Joel M Trugman,2 Yuhua Lin2 1Fatigue Consultation Clinic, Salt Lake City, UT, 2Forest Research Institute, Jersey City, NJ, USA Background: The purpose of this study was to evaluate the safety, tolerability, and ...
Bateman L, Palmer RH, Trugman JM, Lin Y
doaj  

An Efficient Synthesis of Milnacipran Hydrochloride via Reductive Amination of Aldehyde

Journal of Chemistry, 2017
An efficient synthesis of milnacipran hydrochloride has been accomplished. The important application of this paper is the reductive amination of aldehyde to primary amine with water soluble reagents.
Neha Reddy Desireddy, Arava Glory, Krishna Reddy Bhimireddy, Yadagiri Kurra, Ram Reddy   +4 more
doaj   +1 more source

Influence of serotonergic/noradrenergic gene polymorphisms on nausea and sweating induced by milnacipran in the treatment of depression

Neuropsychiatric Disease and Treatment, 2009
Hisashi Higuchi1, Hitoshi Takahashi2, Mitsuhiro Kamata3, Keizo Yoshida41Department of Psychiatry, St. Marianna University, School of Medicine, Kanagawa, Japan; 2Department of Psychiatry, Tokyo Women’s Medical University, School of ...
Hisashi Higuchi, Hitoshi Takahashi, Mitsuhiro Kamata, Keizo Yoshida   +2 more
doaj  

Milnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study

Neuropsychiatric Disease and Treatment, 2015
Tasuku Hashimoto,1,2 Daiji Sakurai,1 Yasunori Oda,1 Tadashi Hasegawa,3 Nobuhisa Kanahara,4 Tsuyoshi Sasaki,3 Hideki Komatsu,3,5 Junpei Takahashi,1,5 Takahiro Oiwa,6 Yoshimoto Sekine,4,5 Hiroyuki Watanabe,1 Masaomi Iyo1,3 1Department of Psychiatry, Chiba
Hashimoto T, Sakurai D, Oda Y, Hasegawa T, Kanahara N, Sasaki T, Komatsu H, Takahashi J, Oiwa T, Sekine Y, Watanabe H, Iyo M   +11 more
doaj  

Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study

Journal of Pain Research, 2014
Philip J Mease,1 Daniel J Clauw,2 Joel M Trugman,3 Robert H Palmer,3 Yong Wang3 1Swedish Medical Center and University of Washington, Seattle, WA, USA; 2Chronic Pain and Fatigue Research Center, University of Michigan Health System, Ann Arbor, MI, USA ...
Mease PJ, Clauw DJ, Trugman JM, Palmer RH, Wang Y   +4 more
doaj  

Antidepressant therapy with milnacipran and venlafaxine

Neuropsychiatric Disease and Treatment, 2010
Lucilla MansuyPierre Fabre Médicament, Toulouse, FranceAbstract: Specific serotonin norepinephrine reuptake inhibitors (SNRIs) have been described as “better tolerated tricyclic antidepressants” or as “boosted&
Lucilla Mansuy
doaj  

Treatment of patients with comorbid depression and diabetes with metformin and milnacipran

Neuropsychiatric Disease and Treatment, 2010
Peter HofmannUniversity Clinic of Psychiatry, Graz Medical University, Graz, AustriaAbstract: Depression is twice as frequent in patients with diabetes as in the general ­population, and has a negative impact on self-care, adherence to treatment,
Peter Hofmann
doaj  

Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group)

Neuropsychiatric Disease and Treatment, 2009
Heidemarie Abrahamian1, Peter Hofmann2, Rudolf Prager1, Hermann Toplak313rd Medical Department, General Hospital Hietzing with Neurological Center Rosenhuegel and Karl Landsteiner Institute for Metabolic Diseases and Nephrology, Vienna, Austria ...
Heidemarie Abrahamian, Peter Hofmann, Rudolf Prager, Hermann Toplak   +3 more
doaj  

New and emerging therapeutic agents for the treatment of fibromyalgia: an update

Journal of Pain Research, 2010
Jill M ReclaIGERT Program in Functional Genomics, Graduate School of Biomedical Sciences, University of Maine and The Jackson Laboratory, Bar Harbor, Maine, USAAbstract: Fibromyalgia (FM) is a chronic widespread pain condition that is estimated to ...
Jill M Recla
doaj